Caxton Associates (New York)’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
Other funds holding PFE
Caxton Associates (New York)'s PFE Position: Q4 2024 in Review
Caxton Associates (New York) reduced its Pfizer (PFE) stake by 21% in Q4 2024, selling an estimated $440K and leaving 60,414 shares worth $1.6M. The position accounts for 0.05% of the portfolio, ranked #131.
Caxton Associates (New York) first reported a position in PFE in Q1 2014 and has held it in 14 quarters since. The position peaked at $151M in Q2 2022. 2,995 funds tracked by Wall St. Rank hold PFE as of Q4 2024.
- Caxton Associates (New York) held 60,414 shares of Pfizer worth $1.6M as of Q4 2024.
- Caxton Associates (New York) sold 16,211 Pfizer shares in Q4 2024, an estimated $440K.
- Pfizer made up 0.05% of Caxton Associates (New York)'s portfolio in Q4 2024, its #131 holding.
- Caxton Associates (New York) first reported a position in Pfizer in Q1 2014 and has held it in 14 quarters since.
- Caxton Associates (New York)'s Pfizer position peaked at $151M in Q2 2022.
- 2,995 funds tracked by Wall St. Rank held Pfizer as of Q4 2024.
Based on Caxton Associates (New York)'s 13F filing for Q4 2024, filed 14 Feb 2025.